Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NASONEX vs NASACORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Corticosteroid with anti-inflammatory activity; binds to glucocorticoid receptors, inhibiting inflammatory mediators like prostaglandins and leukotrienes.
Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.
FDA: Treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children ≥2 years; treatment of nasal polyps in adults ≥18 years.,Off-label: Acute sinusitis, nonallergic rhinitis.
Allergic rhinitis (seasonal and perennial) approved by FDA
Mometasone furoate 200 mcg per day as 2 sprays (50 mcg/spray) in each nostril once daily. May reduce to 100 mcg per day (1 spray per nostril once daily) if symptoms controlled. Maximum 200 mcg per day.
110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.
The terminal elimination half-life of mometasone furoate following intranasal administration is approximately 5.8 hours (range 2.7–11.5 hours) in adults, reflecting rapid clearance from systemic circulation.
Terminal elimination half-life is approximately 3-4 hours after intranasal administration; however, due to prolonged residence time in nasal mucosa, clinical effects persist beyond plasma half-life.
Hepatic metabolism via CYP3A4; desonide undergoes extensive biotransformation.
Primarily hepatic via CYP3A4; main metabolites are 6β-hydroxytriamcinolone acetonide and 21-carboxylic acid derivative.
Mometasone furoate is extensively metabolized in the liver, primarily via CYP3A4, and metabolites are excreted mostly in feces (approximately 74%) and to a lesser extent in urine (approximately 8%).
Primarily hepatic metabolism via CYP3A4; renal excretion accounts for <5% of unchanged drug; biliary/fecal excretion of metabolites accounts for ~60% of total clearance.
Mometasone furoate is approximately 98-99% bound to plasma proteins, primarily albumin.
Approximately 99% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
The volume of distribution at steady state (Vss) is 332 L (approximately 4.5 L/kg for a 70 kg adult), indicating extensive tissue distribution.
Vd is approximately 2-3 L/kg, indicating extensive tissue distribution; clinical significance: large Vd suggests sequestration in tissues, potentially prolonging retention.
Intranasal bioavailability is less than 1% due to low systemic absorption; oral bioavailability is negligible (less than 1% due to extensive first-pass metabolism).
Intranasal: Absolute bioavailability is approximately 3-5% due to extensive first-pass metabolism and limited absorption from nasal mucosa.
No dose adjustment required for renal impairment. No GFR-based guidelines exist.
No dosage adjustment required for renal impairment.
No specific dose adjustment recommended for hepatic impairment. No Child-Pugh based modifications established.
No specific dosage adjustment provided; use with caution in severe hepatic impairment, monitor for systemic effects.
Ages 2–11 years: 1 spray (50 mcg) per nostril once daily (100 mcg total). Ages 12–17 years: same as adult (2 sprays per nostril once daily, 200 mcg total).
Ages 2-5: 55 mcg (1 spray) per nostril once daily, maximum 110 mcg (2 sprays) once daily. Ages 6-11: 110 mcg (2 sprays) per nostril once daily, maximum 220 mcg (4 sprays) once daily. Ages 12+: same as adult.
No specific dose adjustment required. Use same as adult dosing. Monitor for local adverse effects (e.g., epistaxis, nasal irritation) which may be more common in elderly.
No specific adjustment; use lowest effective dose due to potential increased systemic sensitivity; monitor for adverse effects.
None.
No FDA black box warning.
Nasal corticosteroid withdrawal symptoms upon discontinuation,Risk of adrenal suppression with high doses or prolonged use,Increased susceptibility to fungal infections (e.g., Candida albicans),Potential for growth retardation in children,Hoarseness, epistaxis, and nasal septal perforation with misuse
Nasal septal perforation,Nasal irritation,Epistaxis,Candida albicans infection,Immunosuppression,Growth suppression in children,Hypothalamic-pituitary-adrenal axis suppression with prolonged use
Hypersensitivity to any component,Untreated nasal infection (e.g., herpes simplex),Recent nasal surgery or trauma (until healing completed)
Hypersensitivity to triamcinolone acetonide or any excipient,Untreated localized nasal infection
No clinically significant food interactions. Avoid alcohol if it exacerbates rhinitis symptoms.
No significant food interactions known. However, grapefruit juice may slightly increase systemic exposure; avoid excessive consumption.
FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic. There are no adequate and well-controlled studies in pregnant women. Nasonex (mometasone furoate) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Limited data, risk cannot be ruled out. Second trimester: Use with caution if benefit outweighs risk. Third trimester: Potential for fetal adrenal suppression with prolonged use.
FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at relatively low doses. There are no adequate and well-controlled studies in pregnant women. Nasacort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out; avoid unless clearly needed. Second and third trimesters: Limited data; use with caution. Potential fetal risks include orofacial clefts (conflicting data), intrauterine growth restriction, and adrenal suppression in neonates with prolonged maternal use of high doses.
It is not known whether mometasone furoate is excreted in human milk. Because many corticosteroids are excreted in human milk, caution should be exercised when Nasonex is administered to a nursing woman. M/P ratio: Not available.
It is not known whether triamcinolone acetonide is excreted in human breast milk. Because other corticosteroids are excreted in human milk, caution should be exercised when Nasacort is administered to a nursing woman. The M/P ratio is unknown. Low doses via intranasal route are unlikely to produce significant systemic levels; however, consider risk-benefit.
No dose adjustment is recommended based on pharmacokinetic changes in pregnancy. Systemic absorption of intranasal mometasone is minimal; thus, significant pharmacokinetic changes are not expected. Use the lowest effective dose for the shortest duration.
No specific dosing adjustments are recommended for pregnancy based on pharmacokinetic changes. Use the lowest effective dose. Increased plasma volume and altered metabolism during pregnancy may decrease systemic exposure, but intranasal application minimizes systemic absorption. No dose adjustment is typically required, but clinical monitoring for efficacy is advised.
Use the lowest effective dose for the shortest duration. Primarily for seasonal allergic rhinitis; not for acute sinusitis. Monitor for epistaxis and nasal irritation. May cause headache or pharyngitis. Avoid in patients with recent nasal surgery or trauma. Consider intranasal corticosteroids as first-line for moderate to severe allergic rhinitis.
For optimal efficacy, prime the nasal spray by actuating 5 times or until a fine mist appears. If not used for 7+ days, re-prime with 2 actuations. Instruct patient to blow nose gently before use and tilt head slightly forward. Avoid spraying directly onto nasal septum to reduce risk of epistaxis. May cause growth suppression in children; monitor height regularly if long-term use. Onset of action is within 12-24 hours, but maximal effect may take 2-3 weeks.
Use regularly for best results; onset of action may take several days.,Prime the spray before first use or if not used for more than 2 weeks.,Aim spray away from nasal septum to reduce risk of nosebleeds.,Do not use in eyes or mouth.,Inform your doctor if you have a nasal infection or recent nasal surgery.,Side effects may include headache, nosebleed, or throat irritation.
Use regularly for best results; it may take 2-3 weeks for full effect.,Blow your nose gently before each use to clear nasal passages.,Do not spray directly onto the nasal septum (the wall between nostrils).,Clean the nozzle after each use and replace the cap tightly.,If you miss a dose, skip it and continue with the next scheduled dose; do not double the dose.,Common side effects include nosebleeds, headache, and nasal irritation.,Report persistent nosebleeds, vision changes, or signs of infection (e.g., fever) to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NASONEX vs NASACORT, answered by our medical review team.
NASONEX is a Intranasal Corticosteroid that works by Corticosteroid with anti-inflammatory activity; binds to glucocorticoid receptors, inhibiting inflammatory mediators like prostaglandins and leukotrienes.. NASACORT is a Intranasal Corticosteroid that works by Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NASONEX and NASACORT depend on the specific clinical indication. These are both Intranasal Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NASONEX is: Mometasone furoate 200 mcg per day as 2 sprays (50 mcg/spray) in each nostril once daily. May reduce to 100 mcg per day (1 spray per nostril once daily) if symptoms controlled. Maximum 200 mcg per day.. The standard adult dose of NASACORT is: 110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NASONEX and NASACORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NASONEX is classified as Category C. FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic. There are no adequate and well-controlled studies in pregnant women. Nasonex (mometa. NASACORT is classified as Category C. FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at relatively low doses. There are no adequate and well-controlled studies in pregnan. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.